Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway.

Abstract

BACKGROUND The development of a novel BRAF inhibitor, vemurafenib, has been associated with impressive tumor regression in patients with BRAF-positive stage IV melanoma. In the phase 3 clinical trials, dermatologic toxic effects associated with vemurafenib were described, namely, the development of eruptive squamous cell carcinomas. Herein, 3 cases are… (More)
DOI: 10.1001/archdermatol.2012.125

Topics

3 Figures and Tables